144 related articles for article (PubMed ID: 3290714)
1. Overview of the rationale for immunomodulating therapies in multiple sclerosis.
Lisak RP
Neurology; 1988 Jul; 38(7 Suppl 2):5-8. PubMed ID: 3290714
[TBL] [Abstract][Full Text] [Related]
2. The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy.
Kieseier BC; Archelos JJ; Storch M; Gold R; Hartung HP
Wien Klin Wochenschr; 1999 Sep; 111(17):728-37. PubMed ID: 10526397
[TBL] [Abstract][Full Text] [Related]
3. Intensive immunosuppression in multiple sclerosis.
Zaffaroni M; Ghezzi A; Comi G
Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
[TBL] [Abstract][Full Text] [Related]
4. [Multiple sclerosis: a multi-specific immune deficiency disease].
Lamoureux G; Toupin J; Leyva F
Ann Immunol (Paris); 1977; 128(1-2):531-6. PubMed ID: 848902
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: an immunologic perspective.
Cui JY
Phys Med Rehabil Clin N Am; 2005 May; 16(2):351-8. PubMed ID: 15893676
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
Karussis D; Slavin S
J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine and multiple sclerosis: the cons.
Rudge P
Neurology; 1988 Jul; 38(7 Suppl 2):29-30. PubMed ID: 3290712
[TBL] [Abstract][Full Text] [Related]
8. Immunopathogenesis and immunotherapy of multiple sclerosis.
Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
[TBL] [Abstract][Full Text] [Related]
9. The immunopathogenesis of multiple sclerosis.
Prat E; Martin R
J Rehabil Res Dev; 2002; 39(2):187-99. PubMed ID: 12051463
[TBL] [Abstract][Full Text] [Related]
10. Oligoclonal bands and antibody responses in multiple sclerosis.
Correale J; de los Milagros Bassani Molinas M
J Neurol; 2002 Apr; 249(4):375-89. PubMed ID: 11967640
[TBL] [Abstract][Full Text] [Related]
11. Future research directions in multiple sclerosis therapies.
Greenberg BM; Calabresi PA
Semin Neurol; 2008 Feb; 28(1):121-7. PubMed ID: 18256992
[TBL] [Abstract][Full Text] [Related]
12. Contribution of peptides to multiple sclerosis research.
Alcaro MC; Papini AM
Biopolymers; 2006; 84(4):349-67. PubMed ID: 16518843
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of multiple sclerosis.
Weiner HL; Hafler DA
Ann Neurol; 1988 Mar; 23(3):211-22. PubMed ID: 3288084
[TBL] [Abstract][Full Text] [Related]
14. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
15. Antigen-specific therapies in multiple sclerosis.
Sospedra M; Martin R
Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine in multiple sclerosis: the cons.
Silberberg DH
Neurology; 1988 Jul; 38(7 Suppl 2):24-7. PubMed ID: 3290710
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
Fontoura P; Garren H; Steinman L
Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989
[TBL] [Abstract][Full Text] [Related]
18. Future immunotherapies in multiple sclerosis.
Blevins G; Martin R
Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
[TBL] [Abstract][Full Text] [Related]
19. [Recent progress in treatment for multiple sclerosis].
Kira J
Rinsho Shinkeigaku; 2000 Dec; 40(12):1261-3. PubMed ID: 11464473
[TBL] [Abstract][Full Text] [Related]
20. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.
Stinissen P; Raus J
Acta Neurol Belg; 1999 Mar; 99(1):65-9. PubMed ID: 10218096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
